Streetbeat News

Analyst Ratings

AXP

Citigroup analyst Arren Cyganovich maintains a Sell rating on American Express (NYSE:AXP) and lowers the price target from $150 to $148.

Portfolio Pulse from richadhand@benzinga.com

June 16, 2023 | 12:40 pm

MRTX

JMP Securities analyst Silvan Tuerkcan has reiterated a Market Outperform rating on Mirati Therapeutics (NASDAQ:MRTX) and maintained a $61 price target.

Portfolio Pulse from richadhand@benzinga.com

June 16, 2023 | 12:40 pm

LEN

JMP Securities analyst Aaron Hecht reiterated a Market Outperform rating on Lennar (NYSE:LEN) and raised the price target from $115 to $135.

Portfolio Pulse from richadhand@benzinga.com

June 16, 2023 | 12:38 pm

LADR

JMP Securities analyst Steven Delaney reiterated a Market Outperform rating on Ladder Cap (NYSE:LADR) and lowered the price target from $12.5 to $12.

Portfolio Pulse from richadhand@benzinga.com

June 16, 2023 | 12:37 pm

ADBE

Adobe Inc. reported better-than-expected Q2 results with a 10% YoY revenue increase to $4.82 billion, beating the consensus estimate of $4.43 billion. Analysts from Piper Sandler, RBC Capital, Wells Fargo, and Morgan Stanley raised their price targets on Adobe following the earnings announcement.

Portfolio Pulse from Lisa Levin

June 16, 2023 | 12:37 pm

GLPI

JMP Securities analyst Mitch Germain reiterated a Market Outperform rating on Gaming and Leisure Properties (NASDAQ:GLPI) and maintained a $57 price target.

Portfolio Pulse from richadhand@benzinga.com

June 16, 2023 | 12:36 pm

AAP

Morgan Stanley analyst Simeon Gutman maintains an Equal-Weight rating on Advance Auto Parts (NYSE:AAP) and keeps the $80 price target.

Portfolio Pulse from Benzinga Newsdesk

June 16, 2023 | 12:36 pm

DOMO

JMP Securities analyst Patrick Walravens reiterated a Market Outperform rating on Domo (NASDAQ:DOMO) and maintained a $30 price target.

Portfolio Pulse from richadhand@benzinga.com

June 16, 2023 | 12:36 pm

ADBE

Morgan Stanley analyst Keith Weiss maintains an Equal-Weight rating on Adobe (NASDAQ:ADBE) and raises the price target from $470 to $510.

Portfolio Pulse from Benzinga Newsdesk

June 16, 2023 | 12:35 pm

SRPT

RBC Capital analyst Brian Abrahams reiterates an Outperform rating on Sarepta Therapeutics (NASDAQ:SRPT) and maintains a $218 price target.

Portfolio Pulse from richadhand@benzinga.com

June 16, 2023 | 12:35 pm